Protagonist Therapeutics (PTGX) Institutional Ownership

During the previous two years, 226 institutional investors and hedge funds held shares of Protagonist Therapeutics. The most heavily invested institutionals were Farallon Capital Management LLC ($228.90M), RTW Investments LP ($212.24M), Vanguard Group Inc. ($162.89M), State Street Corp ($143.26M), BVF Inc. IL ($73.34M), Pacer Advisors Inc. ($72.43M), and Jefferies Financial Group Inc. ($57.50M).Learn more on PTGX's institutional investors.

98.63% of Protagonist Therapeutics stock is owned by institutional investors. Learn more on PTGX's institutional investor holdings.

Of the 183 institutional investors that purchased Protagonist Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: BVF Inc. IL ($3.83M), Pacer Advisors Inc. ($1.88M), Wellington Management Group LLP ($1.85M), Cowen AND Company LLC ($1.66M), RTW Investments LP ($1.22M), Braidwell LP ($1.13M), and State Street Corp ($1.10M).

Institutional investors have bought a total of 30,493,041 shares in the last 24 months. This purchase volume represents approximately $956.51M in transactions.

Of the 96 institutional investors that sold Protagonist Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: BVF Inc. IL ($1.99M), Kynam Capital Management LP ($1.26M), Farallon Capital Management LLC ($1.04M), Point72 Asset Management L.P. ($985.03K), Deutsche Bank AG ($789.41K), Marshall Wace LLP ($700.37K), and Perceptive Advisors LLC ($671.01K).

Institutional investors have sold a total of 13,563,872 shares in the last 24 months. This volume of shares sold represents approximately $390.62M in transactions.